Skip to: Content
Skip to: Site Navigation
Skip to: Search

July 9, 2008 11:14:44 AM CDT

Learn about Newser Points »

Back to the grid

Nigeria Sues Pfizer Over Deadly Tests

Posted Jun 5, 07 12:35 PM CDT in World,  Business,  Science & Health    Editor's Choice

(Newser) – Nigeria is suing pharma giant Pfizer for $7 billion, claiming the company carried out improper trials on children. 200 children in the state of Kano died, and others developed deformities, after Pfizer tested Trovan, an experimental antibiotic, during a 1996 meningitis outbreak. Nigeria claims the tests were unauthorized, but Pfizer insists the company had consent.

A number of individual families in Kano sued Pfizer after the deaths, but this is the first time Nigeria has filed; Kano is seeking a separate $2.7 billion. BBC analysts surmise that the incident increased Nigerian distrust of Western medicine, complicating the effort to vaccinate the population against polio, which has resurfaced there.

Source BBC

Editor Recommended
The world headquarters of Pfizer Inc. is seen in New York in this April 12, 2005 file photo. Pfizer Chief Executive Jeffrey Kindler proved even those at the top aren't immune to an ongoing company-wide...   (Associated Press)
prev    next
play

Threads (1 of 3)

Tags

children  • medicine  • Nigeria  • Pfizer  • pharma  • meningitis


Loading...

Loading...

Related Threads: Food & Drug Safety, Drug Companies, Really Large Lawsuits

Next story from this section »

Today's Most Popular


Other Home Stories

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »